World's Best Scientists 2026 revealed!

D-Index & Metrics

Immunology

D-Index
53
Citations
17793
World Ranking
3931
National Ranking
153

V H J van der Velden publication distribution in Immunology in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Immunology in 2026. The highlighted bar marks where V H J van der Velden sits on this spectrum.

62–71 publications: 9 scientists 72–81 publications: 23 scientists 82–91 publications: 40 scientists 92–101 publications: 72 scientists 102–111 publications: 86 scientists 112–121 publications: 108 scientists 122–131 publications: 150 scientists 132–141 publications: 160 scientists 142–151 publications: 159 scientists 152–161 publications: 189 scientists 162–171 publications: 166 scientists 172–181 publications: 181 scientists 182–191 publications: 188 scientists 192–201 publications: 187 scientists 202–211 publications: 178 scientists 212–221 publications: 158 scientists 222–231 publications: 168 scientists 232–241 publications: 159 scientists 242–251 publications: 160 scientists 252–261 publications: 148 scientists 262–271 publications: 116 scientists 272–281 publications: 125 scientists 282–291 publications: 115 scientists 292–301 publications: 111 scientists 302–311 publications: 95 scientists 312–321 publications: 97 scientists 322–331 publications: 97 scientists 332–341 publications: 99 scientists 342–351 publications: 96 scientists 352–361 publications: 68 scientists 362–371 publications: 76 scientists 372–381 publications: 71 scientists 382–391 publications: 71 scientists 392–401 publications: 62 scientists 402–411 publications: 54 scientists 412–421 publications: 41 scientists 422–431 publications: 63 scientists 432–441 publications: 53 scientists 442–451 publications: 31 scientists 452–461 publications: 42 scientists 462–471 publications: 40 scientists 472–481 publications: 29 scientists 482–491 publications: 34 scientists 492–501 publications: 30 scientists 502–511 publications: 23 scientists 512–521 publications: 41 scientists 522–531 publications: 29 scientists 532–541 publications: 28 scientists 542–551 publications: 16 scientists 552–561 publications: 18 scientists 562–571 publications: 18 scientists 572–581 publications: 17 scientists 582–591 publications: 17 scientists 592–601 publications: 17 scientists 602–611 publications: 19 scientists 612–621 publications: 13 scientists 622–631 publications: 12 scientists 632–641 publications: 11 scientists 642–651 publications: 16 scientists 652–661 publications: 9 scientists 662–671 publications: 5 scientists 672–681 publications: 13 scientists 682–691 publications: 12 scientists 692–701 publications: 6 scientists 702–711 publications: 6 scientists 712–721 publications: 9 scientists 722–731 publications: 9 scientists 732–741 publications: 6 scientists 742–751 publications: 11 scientists 752–761 publications: 10 scientists 762–771 publications: 7 scientists 772–781 publications: 12 scientists 782–791 publications: 7 scientists 792–801 publications: 5 scientists 802–806 publications: 1 scientists 807+ publications: 100 scientists
62 publications 807+

This scientist: 158 publications — 19th percentile

19% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 807 publications or more.

V H J van der Velden D-index placement in Immunology in 2026

The chart shows the D-index (discipline H-index) distribution of Immunology scientists ranked by Research.com in 2026. The highlighted bar marks where V H J van der Velden sits on this spectrum.

40–41 D-Index: 28 scientists 42–43 D-Index: 91 scientists 44–45 D-Index: 157 scientists 46–47 D-Index: 192 scientists 48–49 D-Index: 175 scientists 50–51 D-Index: 188 scientists 52–53 D-Index: 177 scientists 54–55 D-Index: 155 scientists 56–57 D-Index: 194 scientists 58–59 D-Index: 201 scientists 60–61 D-Index: 197 scientists 62–63 D-Index: 201 scientists 64–65 D-Index: 173 scientists 66–67 D-Index: 167 scientists 68–69 D-Index: 172 scientists 70–71 D-Index: 199 scientists 72–73 D-Index: 184 scientists 74–75 D-Index: 133 scientists 76–77 D-Index: 162 scientists 78–79 D-Index: 127 scientists 80–81 D-Index: 121 scientists 82–83 D-Index: 125 scientists 84–85 D-Index: 121 scientists 86–87 D-Index: 102 scientists 88–89 D-Index: 96 scientists 90–91 D-Index: 75 scientists 92–93 D-Index: 72 scientists 94–95 D-Index: 74 scientists 96–97 D-Index: 66 scientists 98–99 D-Index: 68 scientists 100–101 D-Index: 49 scientists 102–103 D-Index: 60 scientists 104–105 D-Index: 54 scientists 106–107 D-Index: 36 scientists 108–109 D-Index: 23 scientists 110–111 D-Index: 52 scientists 112–113 D-Index: 41 scientists 114–115 D-Index: 34 scientists 116–117 D-Index: 25 scientists 118–119 D-Index: 28 scientists 120–121 D-Index: 11 scientists 122–123 D-Index: 20 scientists 124–125 D-Index: 27 scientists 126–127 D-Index: 19 scientists 128–129 D-Index: 20 scientists 130–131 D-Index: 16 scientists 132–133 D-Index: 17 scientists 134–135 D-Index: 14 scientists 136–137 D-Index: 15 scientists 138–139 D-Index: 9 scientists 140–141 D-Index: 11 scientists 142–143 D-Index: 9 scientists 144–145 D-Index: 9 scientists 146–147 D-Index: 7 scientists 148–149 D-Index: 7 scientists 150–151 D-Index: 7 scientists 152–153 D-Index: 5 scientists 154–155 D-Index: 8 scientists 156 D-Index: 6 scientists 157+ D-Index: 96 scientists
40 D-Index 157+

This scientist: 53 D-Index — 20th percentile

20% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 157 D-Index or more.

Overview

V H J van der Velden is affiliated with Erasmus University Rotterdam in the Netherlands and has a research focus primarily centered in the fields of medicine and biochemistry, genetics, and molecular biology. Their published work extensively covers hematology and oncology topics, among others.

The scientist's main fields of study include:

  • Medicine
  • Biochemistry, Genetics and Molecular Biology

Within these, the notable subfields of interest are:

  • Hematology
  • Public Health, Environmental and Occupational Health
  • Molecular Biology
  • Genetics
  • Oncology

Their primary research topics reflect a concentration on various blood cancers and related treatments:

  • Acute Lymphoblastic Leukemia research
  • Acute Myeloid Leukemia Research
  • Multiple Myeloma Research and Treatments
  • Lymphoma Diagnosis and Treatment
  • Chronic Myeloid Leukemia Treatments
  • Childhood Cancer Survivors' Quality of Life
  • Chronic Lymphocytic Leukemia Research

Van der Velden has contributed to numerous publications, appearing repeatedly in a range of specialized journals. The frequent publication venues include:

  • Blood
  • Leukemia
  • Cytometry Part B Clinical Cytometry
  • HemaSphere
  • Cancers

The scientist's recent papers cover significant topics in hematology and oncology. Some key papers include:

  • Autologous haematopoietic stem-cell transplantation versus bortezomib-melphalan-prednisone, with or without bortezomib-lenalidomide-dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 study, 2020, The Lancet Haematology
  • The KMT2A recombinome of acute leukemias in 2023, 2023, Leukemia
  • A phase 1 study of inotuzumab ozogamicin in pediatric relapsed/refractory acute lymphoblastic leukemia (ITCC-059 study), 2020, Blood
  • Inotuzumab ozogamicin as single agent in pediatric patients with relapsed and refractory acute lymphoblastic leukemia: results from a phase II trial, 2022, Leukemia
  • 41BB-based and CD28-based CD123-redirected T-cells ablate human normal hematopoiesis in vivo, 2020, Journal for ImmunoTherapy of Cancer

The scientist has frequently collaborated with several researchers in their field. Notable co-authors include:

  • Pieter Sonneveld
  • Jacques J. M. van Dongen
  • Edwin Sonneveld
  • Monika Brüggemann
  • Alberto Órfão

Best Publications

  • Standardization and quality control studies of ‘real-time’ quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia – A Europe Against Cancer Program

    J Gabert;E Beillard;V H J van der Velden;W Bi

  • Evaluation of candidate control genes for diagnosis and residual disease detection in leukemic patients using 'real-time' quantitative reverse-transcriptase polymerase chain reaction (RQ-PCR) - a Europe against cancer program

    E Beillard;N Pallisgaard;V H J van der Velden;W Bi

  • EuroFlow antibody panels for standardized n-dimensional flow cytometric immunophenotyping of normal, reactive and malignant leukocytes.

    J J M van Dongen;L Lhermitte;S Böttcher;J Almeida

  • EuroFlow standardization of flow cytometer instrument settings and immunophenotyping protocols

    T Kalina;J Flores-Montero;V H J van der Velden;M Martin-Ayuso

  • Analysis of minimal residual disease by Ig/TCR gene rearrangements: guidelines for interpretation of real-time quantitative PCR data.

    V H J van der Velden;G Cazzaniga;A Schrauder;J Hancock

  • Detection of minimal residual disease in hematologic malignancies by real-time quantitative PCR: principles, approaches, and laboratory aspects.

    V H J van der Velden;A Hochhaus;G Cazzaniga;T Szczepanski

  • The MLL recombinome of acute leukemias in 2017

    C Meyer;T Burmeister;D Gröger;G Tsaur

  • Next Generation Flow for highly sensitive and standardized detection of minimal residual disease in multiple myeloma

    J Flores-Montero;L Sanoja-Flores;B Paiva;N Puig

  • The MLL recombinome of acute leukemias in 2013

    C. Meyer;J. Hofmann;T. Burmeister;D. Gröger

  • Minimal residual disease-directed risk stratification using real-time quantitative PCR analysis of immunoglobulin and T-cell receptor gene rearrangements in the international multicenter trial AIEOP-BFM ALL 2000 for childhood acute lymphoblastic leukemia.

    T Flohr;T Flohr;A Schrauder;G Cazzaniga;R Panzer-Grümayer

  • Targeting of the CD33-calicheamicin immunoconjugate Mylotarg (CMA-676) in acute myeloid leukemia: in vivo and in vitro saturation and internalization by leukemic and normal myeloid cells.

    Vincent H. J. van der Velden;Jeroen G. te Marvelde;Patricia G. Hoogeveen;Irwin D. Bernstein

  • Immunophenotypic differentiation patterns of normal hematopoiesis in human bone marrow: Reference patterns for age-related changes and disease-induced shifts

    E.G. van Lochem;V.H.J. van der Velden;H.K. Wind;J.G. te Marvelde

  • IKZF1 deletions predict relapse in uniformly treated pediatric precursor B-ALL.

    R.P. Kuiper;E. Waanders;V.H. van der Velden;S.V. van Reijmersdal

  • Identification of new microRNA genes and aberrant microRNA profiles in childhood acute lymphoblastic leukemia.

    D Schotte;J C K Chau;G Sylvester;G Liu

  • Selective development of a strong Th2 cytokine profile in high-risk children who develop atopy: risk factors and regulatory role of IFN-gamma, IL-4 and IL-10.

    V. H. J. Van Der Velden;M. P. Laan;M. R. M. Baert;R. De Waal Malefyt

  • Optimization of PCR-based minimal residual disease diagnostics for childhood acute lymphoblastic leukemia in a multi-center setting.

    V H J van der Velden;E R Panzer-Grümayer;G Cazzaniga;T Flohr

  • Prognostic significance of minimal residual disease in infants with acute lymphoblastic leukemia treated within the Interfant-99 protocol

    V H J Van der Velden;L Corral;M G Valsecchi;M W J C Jansen

  • Glucocorticoids: mechanisms of action and anti‐inflammatory potential in asthma

    Unknown

  • Internalization and cell cycle-dependent killing of leukemic cells by Gemtuzumab Ozogamicin: rationale for efficacy in CD33-negative malignancies with endocytic capacity.

    I Jedema;R M Y Barge;V H J van der Velden;B A Nijmeijer

  • Immunoglobulin kappa deleting element rearrangements in precursor-B acute lymphoblastic leukemia are stable targets for detection of minimal residual disease by real-time quantitative PCR.

    V H J van der Velden;M J Willemse;C E van der Schoot;K Hählen

  • Real-time quantitative PCR for detection of minimal residual disease before allogeneic stem cell transplantation predicts outcome in children with acute lymphoblastic leukemia.

    V.H. van der Velden;S.A. Joosten;M.P. Willemse;E.R. van Wering

Frequent Co-Authors

Rob Pieters
Rob Pieters Princess Máxima Center
Giovanni Cazzaniga
Giovanni Cazzaniga University of Milano-Bicocca
Martin Schrappe
Martin Schrappe Kiel University
Hélène Cavé
Hélène Cavé Université Paris Cité
Andrea Biondi
Andrea Biondi University of Milano-Bicocca
Michael Dworzak
Michael Dworzak Medical University of Vienna
Jan Trka
Jan Trka Charles University
Thomas Lion
Thomas Lion Medical University of Vienna
Alberto Orfao
Alberto Orfao University of Salamanca
Rolf Marschalek
Rolf Marschalek Goethe University Frankfurt

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Studying immunology opens up diverse opportunities in healthcare and research fields, many of which can be pursued through flexible online degree programs. For students aiming to enter nursing from a non-nursing background, 12-month accelerated nursing programs online for non nurses offer a fast track to gaining essential clinical skills and licensure.

When selecting a program, ease of admission can be a significant factor. The easiest absn programs to get into provide more accessible entry points without compromising on quality education. Similarly, those interested in becoming licensed practical nurses should consider accredited lpn programs easy to get into, ensuring a smoother application process and quicker entry into the workforce.

Advanced nursing roles, such as nurse practitioners, are critical in immunology-related patient care and research settings. Identifying the easiest np program can help prospective students efficiently plan their educational journey while preparing for specialized career pathways.

Exploring these related online degrees expands career options beyond traditional immunology roles, supporting a broader impact on healthcare through interdisciplinary expertise.

12-month accelerated nursing programs online for non nurses
easiest absn programs to get into
accredited lpn programs easy to get into
easiest np program

Best Scientists Citing V H J van der Velden

Trending Scientists

Recently Published Articles